www.jcimcr.org

JCIMCR OPEN ACCESS Journal of Clinical Images and Medical Case Reports

ISSN 2766-7820

Clinical Image

Open Access, Volume 4

Bleomycin induced flagellate dermatitis: A clinical image

Sai Madhuri Boppana; Bindu Priyanka Vegesana*

Department of Medical Oncology, NRI Academy of Sciences, Chinnakakani, Andhra Pradesh, India.

***Corresponding Author: Bindu Priyanka Vegesana**
Department of Medical Oncology, NRI Academy of Sciences, Chinnakakani, Andhra Pradesh, India.
Tel: +91-7989126093;
Email: priyankavegesana2828@gmail.com

Received: Nov 18, 2023
Accepted: Dec 13, 2023
Published: Dec 20, 2023
Archived: www.jcimcr.org

DOI: www.doi.org/10.52768/2766-7820/2746

Abstract

Bleomycin is a cytostatic antibiotic used in chemotherapy for treating hodgkins lymphoma, testicular and ovarian germ cell tumour cancer. This case is a 18 year old female presenting with bleomycin induced flagellate dermatitis. Characteristics, clinical evaluation and management of bleomycin induced flagellate dermatitis were discussed. Flagellate dermatitis is rare adverse drug reaction that can be self limiting after discontinuation of bleomycin.

Case description

This case is about a 18 year old female who was diagnosed with germ cell tumor of ovary and is currently taking BEP chemotherapy regimen includes bleomycin, etoposide and cisplatin. After the first dose of bleomycin, she presented with hyperpigmented lesions on trunk, back and neck. On examination these lesions are hyperpigmented with a distinct linear aspect on trunk, back and neck were observed. The diagnosis was made by clinical manifestation as flagellate dermatitis. Symptomatic treatment was given with antihistamines, Tablet Levocetrizine-5 mg- H/S and Bleomycin therapy was continued.

Discussion

Bleomycin is a cytostatic antibiotic used in chemotherapy for treating cancer. It is effective in the management of hodgkins lymphoma, testicular and ovarian germ cell tumour [1].

Cutaneous and pulmonary adverse effects are the most commonly associated adverse effects seen with Bleomycin. Bleomycin hydrolase, an enzyme that metabolizes bleomycin, is not found in tissues of skin and lung thereby resulting in the accumulation of bleomycin and making them more susceptible for adverse drug reactions [2]. Flagellate dermatitis, a characteristic cutaneous finding which is often associated with bleomycin, is characterized by features like inflammatory nodules, warty hyperkeratotic plaques with a specific linear arrangement. These nodules or plaques with parallel linear arrangement or curvilinear arrangement often simulates “whiplashes” and therefore it is also known as whiplash dermatitis [3].

In the acute phase of presentation, flagellate dermatitis and fixed drug eruptions share similar histopathological findings such as melanin incontinence, scattered dyskeratotic keratinocytes and vacuolisation in the basal layer of the epidermis [4]. However, during the later stages cutaneous eruptions which are merely post inflammatory changes can be predominantly seen in Flagellate dermatitis [5].

The diagnosis of Flagellate dermatitis will be done by clinical examination of cutaneous features. Flagellate dermatitis triggered by bleomycin is a dose-dependent reaction that often develops at cumulative doses exceeding 100 IU-200 IU. Contrary to this, some patients experience cutaneous reactions following low doses of 10-15 IU [6-8].

No dose adjustments or additional treatment is necessary for the management of bleomycin induced flagellate dermatitis

as it is a self limiting condition and lesions usually resolve after the discontinuation of bleomycin. In the case of severe lesions symptomatic management with antihistamines and/or corticosteroids (topical or oral) should be considered to reduce the ongoing skin trauma and bleomycin therapy may be discontinued. Lesions may recur and spread if bleomycin is reintroduced [9-11].



Figure 1: Linear hyper pigmented lesions of Flagellate dermatitis on back



Figure 2: Detailed hyperpigmented patches on right shoulder

Declarations

Funding: This study is not funded by any organization.

Conflict of interests: We disclose the information with regard to conflict of interest.

Consent for publication: We obtain informed consent from the patient.

References

1. Brandt JP, Gerriets V. Bleomycin. [Updated 2023 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
2. Diao DY, Goodall J. Bleomycin-induced flagellate dermatitis. CMAJ. 2012; 184: 1280.
3. Bhushan P, Manjul P, Baliyan V. Flagellate dermatoses. Indian J Dermatol Venereol Leprol 2014; 80: 149-152.
4. Mowad CM, Nguyen TV, Elenitsas R, et al. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994; 2013: 700–2.
5. Rademaker M, Thomas RH, Meyrick Lowe DG, et al. Linear streaking due to bleomycin. Clin Exp Dermatol. 1987; 2013: 457–9 .
6. Turan Erkek E, Karaali CN, Yılmaz G, Gültürk E. Bleomycin-Induced Flagellate Dermatitis. Turk J Haematol. 2019; 36(2): 138-140. doi: 10.4274/tjh.galenos.2019.2018.0317. Epub 2019 Jan 2. PMID: 30600679; PMCID: PMC6516091
7. Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. 'Flagellate' erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990; 180: 106–109.
8. Biswas A, Julka PK. Bleomycin induced flagellate erythema in a patient with thalamic mixed germ cell tumour: report of a rare adverse effect. J Egypt Natl Canc Inst. 2016; 28: 129–32. doi:10.1016/j.jnci.2016.04.002
9 . Lee H-Y, Lim K-H, Ryu Y, et al.Bleomycin-Induced flagellate erythema: a case report and review of the literature. Oncol Lett 2014; 8: 933 doi:10.3892/ol.2014.2179
10. Le A, Farmakiotis D, Reagan JL. Pruritic rash in a patient with Hodgkin's lymphoma. Cureus 2018; 10: e2450.doi:10.7759/cureus.2450
11. Changal KH, Raina H, Changal QH, et al. Bleomycin-Induced flagellate erythema: a rare and unique drug rash. West Indian Med J 2014; 63: 807–12. .doi:10.7727/wimj.2014.060